Inhibitors of GSK-3 and crystal structures of GSK-3β...

Details Inhibitors of GSK-3 and crystal structures of GSK-3β... Inhibitors of GSK-3 and crystal structures of GSK-3β...

2008-03-28

2010-02-23

Steadman, David J (Department: 1656)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C435S183000, C435S193000, C435S069100, C530S350000

Reexamination Certificate

active

07666647

ABSTRACT:
The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3β or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3β protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3β protein or GSK-3β protein complexes.

REFERENCES:
patent: 4886646 (1989-12-01), Carter et al.
patent: 5096676 (1992-03-01), McPherson et al.
patent: 5130105 (1992-07-01), Carter et al.
patent: 5221410 (1993-06-01), Kushner et al.
patent: 5353236 (1994-10-01), Subbiah
patent: 5400741 (1995-03-01), DeTitta et al.
patent: 6162613 (2000-12-01), Su et al.
patent: 6387641 (2002-05-01), Bellon et al.
patent: WO 92/14211 (1992-08-01), None
patent: WO 93/02209 (1993-02-01), None
patent: WO 94/25860 (1994-11-01), None
patent: WO 98/35048 (1998-08-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/38675 (2000-07-01), None
patent: WO 02/24694 (2002-03-01), None
patent: WO 02/24893 (2002-03-01), None
Giege et al., Crystallogenesis of Biological Macromolecules: Facts and Perspectives. Acta Cryst., 1994, D50: 339-350.
Branden et al., “Introduction to Protein Structure Second Edition”, Garland Publishing Inc., New York, 1999.
Drenth et al. “Principles of X-ray Crystallography,” Springer, New York, 1995.
Kierzek et al. (2001), Biophys Chem 91:1-20.
Wiencek (Ann Rev Biomed Eng, 1999, 1:505-534).
Adams, “Kinetic and Catalytic Mechanisms of Protein Kinases,”Chem. Rev., 101:2271-2290 (2001).
Aoki et al., “Expression, Purification and Crystallization of Human Tau-protein Kinase I/Glycogen Synthase Kinase-3β,”Acta Crystallographica Section D, D56:1464-1465 (2000).
Balbes et al., “A Perspective of Modern Methods in Computer-Aided Drug Design,” in “Reviews in Computational Chemistry,” K.B. Lipkowitz and D.B. Boyd, Eds., VCH Publishers, New York, 5:337-379 (1994).
Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules,” in “Molecular Recognition in Chemical and Biological Problems,” S.M. Roberts, Ed., Royal Society of Chemistry, Special Publication No. 78:182-196 (1989).
Bax et al., “The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Cantenin Phosphorylation,”Structure, 9:1143-1152 (2001).
Bellon et al., “The Structure of Phosphorylated P38γ is Monomeric and Reveals a Conserved Activation-Loop Conformation,”Structure, 7:1057-1065 (1999).
Böhm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors,”J. Comp. Aid. Molec. Design, 6:61-78 (1992).
Bossemeyer et al., “Phosphotransferase and Substrate Binding Mechanishm of the cAMP-Dependent Protein Kinase Catalytic Subunit from Porcine Heart as Deduced from the 2.0 Å Structure of the Complex with Mn2+Adenylyl Imidodiphosphate and Inhibitor Peptide PKI(5-24),”The EMBO Journal, 12:849-859 (1993).
Boulton et al., “ERKs: A Family of Protein-Serine/Threonine Kinases that are Activated and Tyrosine Phosphorylated in Response to Insulin and NGF,”Cell, 65:663-675 (1991).
Brown et al., “Crystallography in the Study of Protein-DNA Interactions,”Methods in Molecular Biology, 56:293-318 (1996).
Brown et al., “The Structural Basis for Specificity of Substrate and Recruitment Peptides for Cyclin-Dependent Kinases,”Nature Cell Biol., 1:438-443 (1999).
Brownlees et al., “Tau Phosphorylation in Transgenic Mice Expressing Glycogen Synthase Kinase-3β Transgenes,”NeuroReport, 8:3251-3255 (1997).
Bryan, “Protein Engineering,”Biotech Adv., 5:221-234 (1987).
Campbell et al., “Diffraction, in Biological Spectroscopy,”The Benjamin/Cummings Publishing Company, Inc., Menlo Park, CA, pp. 299-326 (1984).
Canagarajah et al., “Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation,”Cell, 90:859-869 (1997).
Coghlan et al., “Selective Small Molecule Inhibitors of Glycogen Synthase Kinase-3 Modulate Glycogen Metabolism and Gene Transcription,”Chemistry&Biology, 7:793-803 (2000).
Cohen et al., “Molecular Modeling Software and Methods for Medicinal Chemistry,”J. Med. Chem., 33:883-894 (1990).
Cohen, “Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action,”Biochem. Soc. Trans., 21:555-567 (1993).
Collaborative Computational Project, No. 4, “TheCCP4 Suite: Programs for Protein Crystallography,”Acta Cryst., D50:760-763 (1994).
Cross et al., “The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells between Ras and Raf,”Biochem. J., 303:21-26 (1994).
Dajani et al., “Crystal Structure of Glycogen Synthase Kinase 3β: Structure Basis for Phosphate-Primed Substrate Specificity and Autoinhibition,”Cell, 105:721-732 (2001).
Deeb et al., “Studies on Polyazaindenes Synthesis of Several New Condensed Pyridazine Derivatives,”Collect. Czech. Chem. Commun., 55:2795-2799 (1990).
Ding et al., “Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling,”J. Biol. Chem., 275:32475-32481 (2000).
Eisen et al., “HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site,”Proteins Struct. Funct. Genet., 19:199-221 (1994).
Fang et al., “Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A,”Proc. Natl. Acad. Sci. USA, 97:11960-11965 (2000).
Fox et al. “A Single Amino Acid Substitution Makes ERK2 Susceptible to Pyridinyl Imidazole Inhibitors of p38 MAP Kinase,”Protein Sci., 7:2249-2255 (1998).
Gerstein et al., “Average Core Structures and Variability Measures for Protein Families: Application to the Immunoglobulins,”J. Mol. Biol., 251:161-175 (1995).
Gillet et al., “SPROUT: A Program for Structure Generation,”J. Comp. Aid. Molec. Design, 7:127-153 (1993).
Goldsmith et al., “Protein Kinases,”Current Opinion in Structural Biology, 4:833-840 (1994).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J. Med. Chem., 28:849-857 (1985).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins Struct. Funct. Genet., 8:195-202 (1990).
Guida, “Software for Structure-Based Drug Design,”Curr. Opin. Struct. Biology, 4:777-781 (1994).
Haar et al., “Structure of GSK3β Reveals a Primed Phosphorylation Mechanism,”Nature Structural Biology, 8(7):593-596 (2001).
Hanks et al., “Protein Kinase Catalytic Domain Sequence Database: Identification of Conserved Features of Primary Structure and Classification of Family Members,”Methods in Enzymology, 200:38-62 (1991).
Hanks et al., “The

Affiliated with

Also associated with

Rating

Inhibitors of GSK-3 and crystal structures of GSK-3β... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of GSK-3 and crystal structures of GSK-3β..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of GSK-3 and crystal structures of GSK-3β... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166459